agsqwe

We've been paying ~100 a month for the last 13 years and got an email earlier this month:

"On your next renewal date, August 31, 2026, your account will be transitioned to a Harvest Enterprise plan with Unlimited usage billing.

You will be automatically billed $2,199.50 for your new monthly plan.

You can always downgrade to Flex usage billing, which would have an estimated price of $416.05 and would adapt to your monthly usage.".

Needless to say, after 2 days with Codex the account has been closed.

We like Langfuse for observability via OpenTelemetry. Prompt management is too basic for our needs.

I've had the same issues until I got top of the line Roborock. It never loses map and almost never gets stuck, washes itself with water and drain connection. I'd rather not buy a Chinese brand but here we are...

Then countries with even more greedy elites would have even lower rates, which is not the case.

A few examples of fertility rates (higher is better, 2023 data):

  Sweden: 1.45
  US: 1.62
  Kenya: 3.21

Everything is relative. I'm an immigrant from a post-USSR country and the US is still orders of magnitude more democratic and free

How does it compare to docling?

Who did he took over SpaceX from?

Electrician or plumber

thinking models produce a lot of internal output tokens making them more expensive than non-reasoning models for similar prompt and visible output lengths

It can be relatively safe with proper handling. There are independent laboratories you can send this "product" to for analysis. Often people organize group buys with some random samples tested.

US has Eli Lilly with a competing product (Tirzepatide)

This is very similar to my experience as a software development agency to enterprise customers. Out of big product ideas.

How are you going to make money?

I think what's meant here it's that the manufacturer chose to target specific patient groups (T2D) and commercial insurances to get the highest profit per dose. About 40% of adults in the US are obese, they could have made the drug available at much lower cost and get their profits from economies of scale. Instead, the production is low and the focus is narrow.